Search results for "WHO"

showing 10 items of 829 documents

Expanding the clinical spectrum of COL1A1 mutations in different forms of glaucoma

2016

Background Primary congenital glaucoma (PCG) and early onset glaucomas are one of the major causes of children and young adult blindness worldwide. Both autosomal recessive and dominant inheritance have been described with involvement of several genes including CYP1B1, FOXC1, PITX2, MYOC and PAX6. However, mutations in these genes explain only a small fraction of cases suggesting the presence of further candidate genes. Methods To elucidate further genetic causes of these conditions whole exome sequencing (WES) was performed in an Italian patient, diagnosed with PCG and retinal detachment, and his unaffected parents. Sanger sequencing of the complete coding region of COL1A1 was performed in…

MaleEarly onset glaucomaCOL1A1AdolescentPAX6 Transcription Factorgenetic structures-Collagen Type IMedizinische FakultätHumansGenetics(clinical)Pharmacology (medical)Exomeddc:610Eye ProteinsCongenital glaucomaGlycoproteinsMedicine(all)Homeodomain ProteinsResearchWhole exome sequencingForkhead Transcription FactorsGlaucomaSequence Analysis DNAOsteogenesis Imperfectaeye diseasesCollagen Type I alpha 1 ChainCytoskeletal ProteinsCytochrome P-450 CYP1B1MutationOsteogenesis imperfectasense organsTranscription Factors
researchProduct

Limited cross-border infections in patients newly diagnosed with HIV in Europe

2013

Background: International travel plays a role in the spread of HIV-1 across Europe. It is, however, not known whether international travel is more important for spread of the epidemic as compared to endogenous infections within single countries. In this study, phylogenetic associations among HIV of newly diagnosed patients were determined across Europe.Results: Data came from the SPREAD programme which collects samples of newly diagnosed patients that are representative for national HIV epidemics. 4260 pol sequences from 25 European countries and Israel collected in 2002-2007 were included.We identified 457 clusters including 1330 persons (31.2% of all patients). The cluster size ranged bet…

MaleEpidemiologyHuman immunodeficiency virus (HIV)Human immunodeficiency virus 1HIV Infectionsmedicine.disease_causeVirologie généralephylogenySettore MED/42 - Igiene Generale E ApplicataMen who have sex with menEMERGENCE0302 clinical medicineMedicine and Health SciencesMedicineInfection controlCluster Analysis030212 general & internal medicineIsraelPathologie maladies infectieusestravelPhylogeny0303 health sciencesMolecular EpidemiologyTravelTransmission (medicine)articlevirus transmissionIMMUNODEFICIENCY-VIRUS TYPE-13. Good healthPeer reviewEuropefemaleInfectious DiseasesSUBTYPE BDRUG-RESISTANT HIV-1RNA Viralmale homosexualAdultstructural geneMolecular Sequence DataNewly diagnosedClusters03 medical and health sciencesmaleSDG 3 - Good Health and Well-beingMOLECULAR EPIDEMIOLOGYSWITZERLANDVirologygeographic distributionHumansTransmissionIn patienthuman030304 developmental biologynonhumanMolecular epidemiologybusiness.industryResearchhigh risk populationVirologie médicalenucleotide sequenceSequence Analysis DNAHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequence3121 General medicine internal medicine and other clinical medicineHIV-1businessEurope HIV-1 Transmission ClustersDemographycluster analysis
researchProduct

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

Exploring by whole exome sequencing patients with initial diagnosis of Rubinstein-Taybi syndrome: the interconnections of epigenetic machinery disord…

2019

Rubinstein–Taybi syndrome (RSTS) is an autosomal-dominant neurodevelopmental disease affecting 1:125,000 newborns characterized by intellectual disability, growth retardation, facial dysmorphisms and skeletal abnormalities. RSTS is caused by mutations in genes encoding for writers of the epigenetic machinery: CREBBP (~ 60%) or its homologous EP300 (~ 10%). No causative mutation is identified in up to 30% of patients. We performed whole-exome sequencing (WES) on eight RSTS-like individuals who had normal high-resolution array CGH testing and were CREBBP- and EP300-mutation -negative, to identify the molecular cause. In four cases, we identified putatively causal variants in three genes (ASXL…

MaleGenetic Association StudieCompound heterozygosityWhole Exome SequencingArticleEpigenesis Genetic03 medical and health scienceswhole exome sequencing Rubinstein–Taybi syndrome epigenetic mutationsExome SequencingGeneticsmedicineHumansEpigeneticsEP300ChildGenetics (clinical)Exome sequencingGenetic Association Studies030304 developmental biologyGeneticsRubinstein-Taybi Syndrome0303 health sciencesComparative Genomic HybridizationbiologyRubinstein–Taybi syndrome030305 genetics & heredityInfant NewbornFaciesInfantmedicine.diseaseFacieCREB-Binding ProteinHuman geneticsRSTSKMT2APhenotypeChild PreschoolMutationbiology.proteinNeurodegenerative disordersFemaleHaploinsufficiencyE1A-Associated p300 ProteinHumanHuman genetics
researchProduct

Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants

2007

Objectives Because young infants are at highest risk of pertussis complications, this study assessed whether neonatal acellular pertussis (aP) vaccination could provide earlier immunity. Study design Neonates (n = 121) were randomly assigned (1:1) to receive either aP or hepatitis B vaccine (HBV) (controls) vaccine at birth, followed by vaccination with DTaP-HBV-IPV/Hib at 2, 4 and 6 months. Immune responses were measured. Reactogenicity was assessed for 7 days after each dose. Results The aP birth dose was followed by few adverse events. Reactogenicity of subsequent vaccine doses did not differ between groups. Seven serious adverse events were reported from each group; none were related to…

MaleHBsAgHepatitis B vaccineTime Factorsddc:616.07Bordetella pertussisDrug Administration ScheduleVaccines AcellularDouble-Blind MethodmedicineHumansWhooping coughPertussis VaccineVaccines Acellular/administration & dosageReactogenicityTetanusbusiness.industryDiphtheriaAge FactorsInfant NewbornInfantAntibodies Bacterial/bloodmedicine.diseasePertussis Vaccine/administration & dosageAntibodies BacterialVaccinationImmunoglobulin G/bloodImmunoglobulin GPediatrics Perinatology and Child HealthImmunologyFeasibility StudiesFemalePertactinbusinessBordetella pertussis/immunologyFollow-Up Studies
researchProduct

Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vacc…

2003

Safety, reactogenicity and immunogenicity of GSK Biologicals` hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix(R)hexa) was assessed when used for primary vaccination at 3, 4 and 5 months of age (N = 2163), compared to the separate administration of DTPa-IPV/Hib and HBV vaccines (N = 720). A similar safety and reactogenicity profile was demonstrated for both vaccine regimens, as well as a good immune response for all antigen components. By offering protection against six diseases in it series of single injections, the hexavalent DTPa-HBV-IPV/Hib vaccine was shown to be a safe, well tolerated and immunogenic alternative to primary immunization with licensed separately administered vaccines. (C) …

MaleHaemophilus InfectionsDiphtheria ToxoidWhooping Coughmedicine.disease_causecomplex mixturesHaemophilus influenzaeConjugate vaccinemedicineTetanus ToxoidHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPertussis VaccineReactogenicityTetanusGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationPublic Health Environmental and Occupational HealthInfantDiphtheriamedicine.diseaseHepatitis BVirologyPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyInactivated Poliovirus VaccineMolecular MedicineFemalebusinessPoliomyelitisVaccine
researchProduct

Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant…

1998

With an increasing number of new vaccines available for routine childhood immunization, combination vaccines are needed in order to maintain or achieve a high compliance with recommended immunization programmes. In a prospective, randomized, comparative, multi-centre study, 822 healthy infants were enrolled to receive three doses of either a candidate or a commercially available Haemophilus influenzae type b (Hib) vaccine concomitantly with diphtheria-, tetanus- acellular pertussis (DTaP) vaccine. Study subjects were randomly allocated to one of the following groups: (1) separate, or (2) mixed injection of DTaP and candidate Hib vaccine, or (3) separate injection of DTaP and commercial Hib …

MaleHaemophilus InfectionsWhooping CoughImmunization SecondaryEnzyme-Linked Immunosorbent AssayBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesTetanus ToxoidmedicineHumansProspective StudiesDiphtheria-Tetanus-Pertussis VaccineDiphtheria-Tetanus-acellular Pertussis VaccinesWhooping coughHaemophilus VaccinesAnalysis of VarianceChi-Square DistributionTetanusVaccines ConjugateReactogenicityTetanusbusiness.industryDiphtheriaToxoidInfantDiphtheriamedicine.diseaseAntibodies BacterialHib vaccinePediatrics Perinatology and Child HealthImmunologyFemalebusinessEuropean Journal of Pediatrics
researchProduct

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination.

1999

Abstract Background : Chickenpox and zoster are an important cause of morbidity among children and adults. The ability of a new, thermostable vaccine to induce varicella–zoster-virus (VZV)-specific humoral and cell mediated immunity when given simultaneously with diphtheria–tetanus-acellular pertussis vaccine (DTaP) as a booster dose in the second year of life was investigated. Methods : A new, temperature stable varicella vaccine (OKA-strain, SB-Biologicals, Rixensart, Belgium) was given simultaneously with a booster dose of DTaP vaccine. VZV-specific humoral and cell-mediated immunity was studied in the first 27 out of 232 vaccinated children at 16–28 months of age, from blood samples dra…

MaleHerpesvirus 3 HumanVaricella vaccinevirusesT-LymphocytesImmunization SecondaryBooster dosemedicine.disease_causeAntibodies ViralLymphocyte ActivationChickenpox VaccineInterferon-gammamedicineHumansWhooping coughDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleImmunity CellularChickenpoxintegumentary systemGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusPublic Health Environmental and Occupational HealthVaricella zoster virusvirus diseasesInfantmedicine.diseaseVirologyInterleukin-10VaccinationInfectious DiseasesChild PreschoolImmunoglobulin GImmunologyMolecular MedicinePertussis vaccineFemalebusinessmedicine.drugVaccine
researchProduct

Giovanni Filippo Ingrassia: A five-hundred year-long lesson.

2010

Giovanni Filippo Ingrassia was born five centuries ago in Regalbuto, a small town in the center of Sicily. After his medical course in Padua, under the guidance of Vesalius and Fallopius, he gained international fame as a physician and was recruited as a Professor of human anatomy in Naples and later in Palermo. He is remembered as "the new Galen" or "the Sicilian Hippocrates." He contributed to the knowledge of human anatomy through the description of single bones rather than the whole skeleton. In particular, he was the first to describe the "stapes," the "lesser wings of the sphenoid" and various other structures in the head (probably the pharyngotympanic tube) as well as in the reproduc…

MaleHistologySmall townmedia_common.quotation_subjectBone and BonesOsteologyHonestyWhole skeletonHumansMedicinehuman anatomy medicinSicilyCompetence (human resources)Ear Ossiclesmedia_commonOsteologybusiness.industrySettore BIO/16 - Anatomia UmanaGeneral MedicineAnatomylanguage.human_languageScientific cultureHistory 16th CenturyHuman anatomylanguageAnatomybusinessSicilianClassicsPenis
researchProduct

Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats

2015

Chronic nitroglycerin (GTN) anti-ischemic therapy induces side effects such as nitrate tolerance and endothelial dysfunction. Both phenomena could be based on a desensitization/oxidation of the soluble guanylyl cyclase (sGC). Therefore, the present study aims at investigating the effects of the therapy with the sGC activator BAY 60-2770 and the sGC stimulator BAY 41-8543 on side effects induced by chronic nitroglycerin treatment. Male Wistar rats were treated with nitroglycerin (100mg/kg/d for 3.5days, s.c. in ethanol) and BAY 60-2770 (0.5 or 2.5mg/kg/d) or BAY 41-8543 (1 and 5mg/kg/d) for 6days. Therapy with BAY 60-2770 but not with BAY 41-8543 improved nitroglycerin-triggered endothelial …

MaleHydrocarbons FluorinatedPhysiologyMorpholinesReceptors Cytoplasmic and NuclearVasodilationStimulationPharmacologymedicine.disease_causeBenzoatesNitric oxideNitroglycerinchemistry.chemical_compoundOrgan Culture TechniquesSoluble Guanylyl CyclasemedicineAnimalsPharmacology (medical)Rats WistarEndothelial dysfunctionAortaWhole bloodPharmacologyNitratesActivator (genetics)business.industryNitrotyrosineBiphenyl Compoundsmedicine.diseaseRatsBiphenyl compoundEnzyme ActivationOxidative StressPyrimidineschemistryGuanylate CyclaseMeeting Abstractcardiovascular systemMolecular MedicineSoluble guanylyl cyclasebusinessOxidative stressBMC Pharmacology and Toxicology
researchProduct